Patents Assigned to SHORLA PHARMA LTD.
  • Stable formulations comprising thiotepa
    Patent number: 12622921
    Abstract: The present disclosure provides pharmaceutical compositions comprising thiotepa and one selected from PEG, such as PEG400 or PEG600, and DMSO, and optionally water or an aqueous saline solution and thiosulfate. The composition is free or substantially free of impurities. Also provided is a method for treating cancer in a subject, or myeloablation prior to bone marrow transplantation using the composition. A method for enhancing the stability of a thiotepa formulation is also contemplated.
    Type: Grant
    Filed: August 29, 2022
    Date of Patent: May 12, 2026
    Assignee: SHORLA PHARMA LTD.
    Inventors: Sharon Cunningham, Orlaith Ryan, Johannes Jan Platteeuw
  • Stable formulations comprising thiotepa
    Patent number: 11975013
    Abstract: The present disclosure provides pharmaceutical compositions comprising thiotepa and one selected from PEG, such as PEG400 or PEG600, and DMSO, and optionally water or an aqueous saline solution and thiosulfate. The composition is free or substantially free of impurities. Also provided is a method for treating cancer in a subject, or myeloablation prior to bone marrow transplantation using the composition. A method for enhancing the stability of a thiotepa formulation is also contemplated.
    Type: Grant
    Filed: September 1, 2022
    Date of Patent: May 7, 2024
    Assignee: SHORLA PHARMA LTD.
    Inventors: Sharon Cunningham, Orlaith Ryan, Johannes Jan Platteeuw